Effect of e-Cigarettes Plus Counseling vs Counseling Alone on Smoking Cessation: A Randomized Clinical Trial.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
10 11 2020
Historique:
entrez: 10 11 2020
pubmed: 11 11 2020
medline: 20 11 2020
Statut: ppublish

Résumé

Electronic cigarettes (e-cigarettes) for smoking cessation remain controversial. To evaluate e-cigarettes with individual counseling for smoking cessation. A randomized clinical trial enrolled adults motivated to quit smoking from November 2016 to September 2019 at 17 Canadian sites (801 individuals screened; 274 ineligible and 151 declined). Manufacturing delays resulted in early termination (376/486 participants, 77% of target). Outcomes through 24 weeks (March 2020) are reported. Randomization to nicotine e-cigarettes (n = 128), nonnicotine e-cigarettes (n = 127), or no e-cigarettes (n = 121) for 12 weeks. All groups received individual counseling. The primary end point was point prevalence abstinence (7-day recall, biochemically validated using expired carbon monoxide) at 12 weeks, changed from 52 weeks following early termination. Participants missing data were assumed to be smoking. The 7 secondary end points, examined at multiple follow-ups, were point prevalence abstinence at other follow-ups, continuous abstinence, daily cigarette consumption change, serious adverse events, adverse events, dropouts due to adverse effects, and treatment adherence. Among 376 randomized participants (mean age, 52 years; 178 women [47%]), 299 (80%) and 278 (74%) self-reported smoking status at 12 and 24 weeks, respectively. Point prevalence abstinence was significantly greater for nicotine e-cigarettes plus counseling vs counseling alone at 12 weeks (21.9% vs 9.1%; risk difference [RD], 12.8 [95% CI, 4.0 to 21.6]) but not 24 weeks (17.2% vs 9.9%; RD, 7.3 [95% CI, -1.2 to 15.7]). Point prevalence abstinence for nonnicotine e-cigarettes plus counseling was not significantly different from counseling alone at 12 weeks (17.3% vs 9.1%; RD, 8.2 [95% CI, -0.1 to 16.6]), but was significantly greater at 24 weeks (20.5% vs 9.9%; RD, 10.6 [95% CI, 1.8 to 19.4]). Adverse events were common (nicotine e-cigarette with counseling: 120 [94%]; nonnicotine e-cigarette with counseling: 118 [93%]; counseling only: 88 [73%]), with the most common being cough (64%) and dry mouth (53%). Among adults motivated to quit smoking, nicotine e-cigarettes plus counseling vs counseling alone significantly increased point prevalence abstinence at 12 weeks. However, the difference was no longer significant at 24 weeks, and trial interpretation is limited by early termination and inconsistent findings for nicotine and nonnicotine e-cigarettes, suggesting further research is needed. ClinicalTrials.gov Identifier: NCT02417467.

Identifiants

pubmed: 33170240
pii: 2772759
doi: 10.1001/jama.2020.18889
pmc: PMC7656286
doi:

Banques de données

ClinicalTrials.gov
['NCT02417467']

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1844-1854

Subventions

Organisme : CIHR
Pays : Canada

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Am J Health Behav. 2005 Sep-Oct;29(5):443-55
pubmed: 16201861
N Engl J Med. 2018 Jun 14;378(24):2302-2310
pubmed: 29791259
PLoS One. 2013 Jun 24;8(6):e66317
pubmed: 23826093
BMJ Open. 2015 Jan 13;5(1):e006229
pubmed: 25586367
MMWR Morb Mortal Wkly Rep. 2020 Jan 17;69(2):44-49
pubmed: 31945038
CJC Open. 2020 Mar 19;2(3):168-175
pubmed: 32462131
N Engl J Med. 2020 Feb 20;382(8):697-705
pubmed: 31860793
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
Am J Respir Crit Care Med. 2018 Feb 15;197(4):492-501
pubmed: 29053025
Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1795-1803
pubmed: 29127080
Am J Respir Crit Care Med. 2019 Dec 1;200(11):1392-1401
pubmed: 31390877
Nicotine Tob Res. 2002 May;4(2):149-59
pubmed: 12028847
J Am Board Fam Med. 2019 Jul-Aug;32(4):567-574
pubmed: 31300577
BMC Med. 2015 Oct 12;13:257
pubmed: 26456865
Lancet Respir Med. 2020 Jan;8(1):54-64
pubmed: 31515173
Eur J Public Health. 2017 Feb 1;27(1):129-134
pubmed: 28177479
Lancet. 2013 Nov 16;382(9905):1629-37
pubmed: 24029165
CMAJ. 2008 Jul 15;179(2):135-44
pubmed: 18625984
J Consult Clin Psychol. 2004 Jun;72(3):371-81
pubmed: 15279521
Nicotine Tob Res. 2016 Oct;18(10):1937-1943
pubmed: 26783292
Am J Respir Crit Care Med. 2018 Jul 1;198(1):67-76
pubmed: 29481290
Nicotine Tob Res. 2019 Jan 1;21(1):119-126
pubmed: 29660034
N Engl J Med. 2019 Feb 14;380(7):629-637
pubmed: 30699054

Auteurs

Mark J Eisenberg (MJ)

Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.
Departments of Medicine and Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada.
Division of Cardiology, Jewish General Hospital, Montréal, Québec, Canada.

Andréa Hébert-Losier (A)

Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.

Sarah B Windle (SB)

Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.

Todd Greenspoon (T)

Hamilton Community Health Centre, Family Health Organization, Hamilton, Ontario, Canada.

Tim Brandys (T)

Ottawa Hospital, Ottawa, Ontario, Canada.

Tamàs Fülöp (T)

Centre de recherche sur le vieillissement, Sherbrooke, Québec, Canada.

Thang Nguyen (T)

St Boniface Hospital, Winnipeg, Manitoba, Canada.

Stéphane Elkouri (S)

Division of Vascular Surgery, Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.

Martine Montigny (M)

Centre intégré de santé et de services sociaux de Laval, Hôpital Cité-de-la-Santé, Laval, Québec, Canada.

Igor Wilderman (I)

Wilderman Medical Clinic/Canadian Centre for Clinical Trials, Thornhill, Ontario, Canada.

Olivier F Bertrand (OF)

Institut de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec City, Québec, Canada.

Joanna Alexis Bostwick (JA)

Hôpital Montfort, Ottawa, Ontario, Canada.

John Abrahamson (J)

Michael Garron Hospital, Toronto, Ontario, Canada.

Yves Lacasse (Y)

Institut de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec City, Québec, Canada.

Smita Pakhale (S)

The Ottawa Hospital Research Institute/The Bridge Engagement Centre, Ottawa, Ontario, Canada.

Josselin Cabaussel (J)

Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.

Kristian B Filion (KB)

Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.
Departments of Medicine and Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH